Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
Dermatol Surg. 2013 Nov;39(11):1621-9. doi: 10.1111/dsu.12340. Epub 2013 Nov 1.
Midface volume loss and contour deficiency are often treated using soft-tissue fillers capable of elevating and supporting facial features.
To evaluate the effectiveness and safety of large gel particle hyaluronic acid with 0.3% lidocaine (LGP-HA-L) for the treatment of midface volume loss or contour deficiency.
This 24-week, open-label study recruited adults aged 18 to 65 with bilateral moderate to substantial midface volume loss or contour deficiency (Medicis Midface Volume Scale (MMVS) score 3-4). The primary effectiveness measure was MMVS response (≥1-grade improvement) 8 weeks after treatment according to evaluators blinded to injection volume.
All enrolled patients (n = 40; 85.0% female; mean ± SD age 53.1 ± 7.0 years) completed the study. Mean ± SD injected volume for both sides of the midface was 5.3 ± 2.5 mL. Week 8 MMVS response rates were 97.5% according to blinded evaluators and treating investigators and 90.0% according to patients; week 24 rates were 90.0%, 92.5%, and 82.5%, respectively. Global Aesthetic Improvement Scale response rates were 95.0% to 100.0% throughout the study. Adverse events were reported in 60.0% of patients and were mild or moderate; all resolved by study end and most within 1 week.
Midface volume loss or contour deficiency may be safely and effectively corrected using LGP-HA-L.
中面部容积缺失和轮廓缺陷通常采用可提升和支撑面部特征的软组织填充剂进行治疗。
评估含 0.3%利多卡因的大颗粒凝胶型透明质酸(LGP-HA-L)治疗中面部容积缺失或轮廓缺陷的有效性和安全性。
这是一项为期 24 周的开放性标签研究,招募了年龄在 18 至 65 岁之间、双侧中面部存在中度至重度容积缺失或轮廓缺陷(Medicis 中面部容积量表(MMVS)评分为 3-4 分)的成年人。主要有效性指标为治疗 8 周后根据评估者(不了解注射量)评估的 MMVS 应答(改善≥1 级)。
所有入组患者(n=40;85.0%为女性;平均年龄 53.1±7.0 岁)均完成了研究。中面部两侧的平均注射量为 5.3±2.5 mL。根据盲法评估者和治疗研究者评估,第 8 周 MMVS 应答率为 97.5%,根据患者评估为 90.0%;第 24 周的应答率分别为 90.0%、92.5%和 82.5%。整个研究期间,全球美学改善量表的应答率为 95.0%至 100.0%。60.0%的患者报告发生了不良事件,均为轻度或中度;所有不良事件在研究结束时均得到解决,大多数在 1 周内得到解决。
使用 LGP-HA-L 可安全有效地矫正中面部容积缺失或轮廓缺陷。